Cargando…
Fatal Disseminated Tuberculosis during Treatment with Ruxolitinib Plus Prednisolone in a Patient with Primary Myelofibrosis: A Case Report and Review of the Literature
A 73-year-old man with primary myelofibrosis (PMF) was being treated with hydroxyurea, which was changed to ruxolitinib treatment because of worsening constitutional symptoms. Although ruxolitinib rapidly induced relief, he developed a high-grade fever. A comprehensive fever work-up found no apparen...
Autores principales: | Tsukamoto, Yasuhiro, Kiyasu, Junichi, Tsuda, Mariko, Ikeda, Motohiko, Shiratsuchi, Motoaki, Ogawa, Yoshihiro, Yufu, Yuji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Japanese Society of Internal Medicine
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5980814/ https://www.ncbi.nlm.nih.gov/pubmed/29279479 http://dx.doi.org/10.2169/internalmedicine.9165-17 |
Ejemplares similares
-
Ruxolitinib for myelofibrosis
por: GU, LIAN, et al.
Publicado: (2013) -
Fatal Disseminated Tuberculosis and Concurrent Disseminated Cryptococcosis in a Ruxolitinib-treated Patient with Primary Myelofibrosis: A Case Report and Literature Review
por: Ogai, Asuka, et al.
Publicado: (2021) -
Ruxolitinib in Myelofibrosis and Polycythemia Vera
por: Wolfe, Leah
Publicado: (2016) -
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
por: Manduzio, Palma
Publicado: (2017) -
Efficacy of ruxolitinib on hepatomegaly in patients with myelofibrosis
por: Verstovsek, S, et al.
Publicado: (2016)